Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Cabozantinib S-malate

Review the clinical trials studying cabozantinib s-malate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-21 of 21

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Location: 480 locations
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients with Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Status: Active
Location: 201 locations
Testing Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Kidney Cancer, PAPMET2 Trial
Status: Active
Location: 166 locations
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients with Newly Diagnosed Osteosarcoma
Status: Active
Location: 137 locations
Using Nivolumab Alone or with Cabozantinib to Prevent Mucosal Melanoma Return after Surgery
Status: Active
Location: 137 locations
Testing Nivolumab and Ipilimumab Immunotherapy with or without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
Status: Active
Location: 90 locations
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Status: Active
Location: 44 locations
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Status: Active
Location: 17 locations
Cabozantinib-s-malate in Treating Patients with Non-small Cell Lung Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Location: 8 locations
Cabozantinib to Prevent Progression or Recurrence in Patients with High-Risk Pediatric Solid Tumors
Status: Active
Location: 6 locations
Pembrolizumab and Cabozantinib in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer That Cannot Be Removed by Surgery
Status: Active
Location: 3 locations
Cabozantinib in Combination with Pembrolizumab for the Treatment of Patients with Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Status: Active
Location: 3 locations
Cabozantinib and Isotretinoin in Treating Children with Relapsed or Refractory Solid Tumors
Status: Active
Location: 3 locations
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Status: Active
Location: 3 locations
Cabozantinib, Ipilimumab, Nivolumab, and Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma
Status: Active
Location: 2 locations
Cabozantinib for the Treatment of High Grade Neuroendocrine Neoplasms
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
A Dendritic Cell Vaccine in Combination with Cabozantinib for Altering the Immune System in Patients with Localized Clear Cell Renal Cell Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer with a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Cabozantinib and Durvalumab with or without Tremelimumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Tumor Treating Fields Therapy in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas